Skip to content

Observational study on the efficacy of intradermal injection of autologous platelet-rich plasma in repairing the damage and anti-aging of skin mucosa and its appendages

Observational study on the efficacy of intradermal injection of autologous platelet-rich plasma in repairing the damage and anti-aging of skin mucosa and its appendages

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075168
Enrollment
Unknown
Registered
2023-08-28
Start date
2023-09-25
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin

Interventions

Observation of skin mucosa and its appendages injury and senescence and voluntary treatment by microneedle injection of autologous platelet-rich plasma:NA

Sponsors

Affiliated Sixth People's Hospital, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) normal health, no infectious diseases, blood diseases, mental diseases, active diseases and serious skin diseases (local ulcers or infections, etc.); (2) have not received any facial cosmetic treatment within 2 months; (3) No history of skin allergy; (4) Normal venous blood platelet count range (100×10^9/L~300×10^9/L); (5) 3 months before blood collection, no drugs affecting platelet function and drugs and health products related to the function of the test; (6) No bad habits (such as smoking, alcohol, drugs, etc.) during pregnancy and lactation.

Exclusion criteria

Exclusion criteria: (1) Grade 3 or 4 gastrointestinal bleeding or varicose bleeding that required blood transfusion or endoscopic or surgical intervention in the 3 months prior to the first dose; (2) People with active hepatitis B (HBSAG and/or HBSAG core antibody positive with =103 copies /mL of HBV-DNA or =200IU/mL) or hepatitis C (HCV antibody positive and/or HCV-RNA positive) requiring treatment; (3) A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation, or a history of allogeneic bone marrow transplantation; (4) Moderate or severe heart disease; (5) The researcher believes that the subjects are not suitable for participating in this study for other reasons.

Design outcomes

Primary

MeasureTime frame
The proportion and rate of improvement of skin moisture, elasticity, stain, oil, scar area and hair growth before and after treatment.;

Secondary

MeasureTime frame
Subjective evaluation of patients' psychology before and after treatment.;

Countries

China

Contacts

Public ContactHui Deng

Affiliated Sixth People's Hospital, Shanghai Jiaotong University

xuri1104@163.com+86 189 3017 4575

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026